Navigation Links
Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy

Results from the first clinical trial of a therapeutic cancer vaccine combining the synthetic bacterial DNA sequence, CpG 7909 (ProMuneTM, Coley Pharmaceutical), with a peptide antigen were reported today in the Journal of Clinical Investigation. The paper shows that the CpG 7909 DNA sequence is safe, and increases the immune system's ability to recognize and destroy cancer cells. The Phase I study was conducted by the Lausanne Branch of the Ludwig Institute for Cancer Research (LICR) at the Lausanne University Hospital in Switzerland, in the framework of the international Cancer Vaccine Collaborative (CVC), a partnership established by the New York-based Cancer Research Institute (CRI) and the LICR.

"What we're doing is testing a novel adjuvant, a compound that stimulates the immunological response to a vaccine, which is essentially tricking the immune system into thinking the vaccine is a bacterial infection," says lead author Dr. Daniel Speiser from the LICR Lausanne Branch. "The immune system mounts a response against the peptide antigen, the cancer-specific target, in the vaccine, and thus also against the antigen on the cancer cells."

The vaccine, combining the CpG 7909 adjuvant and Incomplete Freund's Adjuvant (IFA) with a synthetic peptide (protein fragment) from a melanoma antigen known as Melan-A/MART-1, induced CD8+ T cells that specifically recognized cells displaying Melan-A/MART-1 on their surface. This T cell response occurred in all eight patients in the trial. Responses were one order of magnitude higher than those observed in eight patients who received the Melan-A/MART-1 antigen with IFA but without CpG 7909 in previous studies.

According to Dr. Jill O'Donnell-Tormey, the Executive Director of CRI, the trial is part of the CVC's systematic, coordinated vaccine development approach that compares single vaccine variables in parallel. "We've identified many cancer antigens, and the challenge is to determine which cancer vaccine compositions induce a strong and sustained immune response against particular antigens. The results from this trial represent a substantial step forward in this regard. This conclusion is justified because we are using reproducible immunological monitoring across the CVC, allowing a more accurate comparison of the effects of CpG 7909 in this trial with the results of several other adjuvants that have been tested in other trials. By comparing single variables in parallel we believe we can develop effective cancer vaccines in a much shorter time than the conventional approach of trying variables sequentially." The CVC has clinical research sites in Australia, Belgium, Germany, Japan, Switzerland, the UK and the USA.


'"/>

Source:Ludwig Institute For Cancer Research


Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. EuroVacc 02 HIV Vaccine Trial Begins
8. Active Vaccine Prevents Mice From Developing Prion Disease
9. New Vaccine To Be Used For First Time In Polio Outbreak Response
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/22/2020)... ... July 21, 2020 , ... USDM Life ... and compliance, announces a new solution to manage regulated workloads on Microsoft Azure. ... their technology stack complies with FDA and global regulations. USDM's new managed service ...
(Date:7/10/2020)... FALLS CHURCH, Va. (PRWEB) , ... July 08, ... ... , The Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, ... product may need a comparability study, but what is the most effective way ...
(Date:7/2/2020)... REDWOOD CITY, Calif. (PRWEB) , ... July 01, ... ... stage biotech company, presented its phase 1a findings of Neihulizumab, a biologic for ... annual conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. ... can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI ... two switches in a push-pull configuration; yielding fast fall time for a capacitive ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... industry, today announced the release of its signature product called Beacon - ... (MSLs) and other field medical professionals. , Beacon helps MSLs streamline ...
(Date:7/18/2020)... ... July 17, 2020 , ... ... the life sciences and food industries, is pleased to announce that Charles Galea ... – Business Development. , Charles is an accomplished and results-driven sales executive with ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering ... to 200 million stem cells. Depending on the patient's condition, treatment may be offered ... will die having some form of Alzheimers dementia, and the incidence continues to increase ...
Breaking Biology Technology: